Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery

Human Gene Therapy

Volumn 17, Issue 1, 2006, Pages 117-124

  Pirollo, Kathleen F ^a   Zon, Gerald ^b   Rait, Antonina ^a   Zhou, Qi ^a   Yu, Wei ^a   Hogrefe, Richard ^b   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b TriLink BioTechnologies Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ANTISENSE OLIGONUCLEOTIDE; FLUORESCEIN; IMMUNOLIPOSOME; NANOPARTICLE; PLASMID DNA; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEX FORMATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SYNTHESIS; DRUG TARGETING; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN;

ANIMALS; CELL LINE, TUMOR; GENE TRANSFER TECHNIQUES; GENITAL NEOPLASMS, MALE; HUMANS; LIPOSOMES; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NANOSTRUCTURES; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; RECEPTORS, TRANSFERRIN; RNA, SMALL INTERFERING; SEMINAL VESICLES; SENSITIVITY AND SPECIFICITY;

ANIMALIA;

EID: 30744457637     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2006.17.117     Document Type: Article

References (30)

1. ALISAUSKUS, R., WONG, G., and GOLD, D. (1995). Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Res. 55, 5743s-5748s.
2. BATRA, J.K., FITZGERALD, D.J., CHAUDHARY, V.K., and PASTAN, I. (1991). Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: Anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). Mol. Cell. Biol. 11, 2200-2205.
3. CAPLEN, N.J. (2004). Gene therapy progress and prospects. Down-regulating gene expression: The impact of RNA interference. Gene Ther. 11, 1241-1248.
4. CAPLEN, N.J., and MOUSSES, S. (2003). Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells. Ann. N.Y. Acad. Sci. 1002, 56-62.
5. CHENG, P.W. (1996). Receptor ligand-facilitated gene transfer: Enhancement of liposome-mediated gene transfer and expression by transferrin. Hum. Gene Ther. 7, 275-282.
6. CRISTIANO, R.J., and CURIEL, D.T. (1996). Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway. Cancer Gene Ther. 3, 49-57.
7. ELBASHIR, S.M., HARBORTH, J., LENDECKEL, W., YALCIN, A., WEBER, K., and TUSCHL, T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498.
8. ELLIOTT, R.L., ELLIOTT, M.C., WANG, F., and HEAD, J.F. (1993). Breast carcinoma and the role of iron metabolism: A cytochemical, tissue culture, and ultrastructural study. Ann. N.Y. Acad. Sci. 698, 159-166.
9. HANNON, G.J. (2002). RNA interference. Nature 418, 244-251.
10. HAYNES, B.F., HEMLER, M., COTNER, T., MANN, D.L., EISENBARTH, G.S., STROMINGER, J.L., and FAUCI, A.S. (1981). Characterization of a monoclonal antibody (5E9) that defines a human cell surface antigen of cell activation. J. Immunol. 127, 347-351.
11. LEONESSA, F., GREEN, D., LICHT, T., WRIGHT, A., WINGATE-LEGETTE, K., LIPPMAN, J., GOTTESMAN, M.M., and CLARKE, R. (1996). MDA435/LCC6 and MDA435/LCC6MDR1: Ascites models of human breast cancer. Br. J. Cancer 73, 154-161.
12. LU, P.Y., XIE, F.Y., and WOODLE, M.C. (2003). siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr. Opin. Mol. Ther. 5, 225-234.
13. MARTINEZ, J., PATKANIOWSKA, A., URLAUB, H., LUHRMANN, R., and TUSCHL, T. (2002). Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 110, 563-574.
14. MORRISSEY, D.V., LOCKRIDGE, J.A., SHAW, L., BLANCHARD, K., JENSEN, K., BREEN, W., HARTSOUGH, K., MACHEMER, L., RADKA, S., JADHAV, V., VAISH, N., ZINNEN, S., VARGEESE, C., BOWMAN, K., SCHAFFER, C.S., JEFFS, L.B., JUDGE, A., MACLACHLAN, I., and POLISKY, B. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007.
15. PIROLLO, K.F., DAGATA, J., WANG, P., FREEDMAN, M., VLADAR, A., FRICKE, S., LLEVA, L., ZHOU, Q., and CHANG, E.H. (2005). A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Molecular Imaging 5, (in press).
16. PONKA, P., and LOK, C.N. (1999). The transferrin receptor: Role in health and disease. Int. J. Biochem. Cell Biol. 31, 1111-1137.
17. RAIT, A.S., PIROLLO, K.F., XIANG, L., ULICK, D., and CHANG, E.H. (2002). Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol. Med. 8, 475-486.
18. RAIT, A.S., PIROLLO, K., ULICK, D., CULLEN, K.J., and CHANG, E.H. (2003). HER-2-targeted antisense oglionucleotide results in sensitization of head and neck cancer cells to chemotherapeutic agents. Ann. N.Y. Acad. Sci. 1002, 78-89.
19. RYTHER, R.C., FLYNT, A.S., PHILLIPS, J.A., III, and PATTON, J.G. (2005). siRNA therapeutics: Big potential from small RNAs. Gene Ther. 12, 5-11.
20. SCANLON, K.J. (2004). Cancer gene therapy: Challenges and opportunities. Anticancer Res. 24, 501-504.
21. SCHIFFELERS, R.M., ANSARI, A., XU, J., ZHOU, Q., TANG, Q., STORM, G., MOLEMA, G., LU, P.Y., SCARIA, P.V., and WOODLE, M.C. (2004). Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res. 32, e149.
22. SIOUD, M., and SORENSEN, D.R. (2003). Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem. Biophys. Res. Commun. 312, 1220-1225.
23. SONG, E., ZHU, P., LEE, S.K., CHOWDHURY, D., KUSSMAN, S., DYKXHOORN, D.M., FENG, Y., PALLISER, D., WEINER, D.B., SHANKAR, P., MARASCO, W.A., and LIEBERMAN, J. (2005). Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23, 709-717.
24. URBAN-KLEIN, B., WERTH, S., ABUHARBEID, S., CZUBAYKO, F., and AIGNER, A. (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12, 461-466.
25. XU, L., PIROLLO, K., TANG, W., RAIT, A., and CHANG, E.H. (1999a). Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum. Gene Ther. 10, 2941-2952.
26. XU, L., PIROLLO, K., RAIT, A., MURRAY, A., and CHANG, E.H. (1999b). Systemic p53 gene therapy in combination with radiation results in human tumor regression. Tumor Targeting 4, 92-104.
27. XU, L., TANG, W.H., HUANG, C.C., ALEXANDER, W., XIANG, L.M., PIROLLO, K., RAIT, A., and CHANG, E.H. (2001). Systemic p53 gene therapy of cancer with immunolipoplexes targeted by antitransferrin receptor scFv. Mol. Med. 7, 723-734.
28. XU, L., HUANG, C.-C., HUANG, W.-Q., TANG, W.-H., RAIT, A., YIN, Y., CRUZ, I., XIANG, L.-M., PIROLLO, K., and CHANG, E.H. (2002). Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. Mol. Cancer Ther. 1, 337-346.
29. YANG, M., JIANG, P., SUN, F.-S., HASEGAWA, S., BARANOV, E., CHISHIMAT, S.H., MOOSSA, A.R., and HOFFMAN, R.M. (1999). A fluorescent orthotopic bone metastasis model of human prostate cancer. Cancer Res. 59, 781-786.
30. YU, W., PIROLLO, K.F., YU, B., RAIT, A., XIANG, L., HUANG, W., ZHOU, Q., ERTEM, G., and CHANG, E.H. (2004). Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. Nucleic Acids Res. 32, e48.